Artificial Intelligence in Non-Insulin-Treated Type 2 Diabetes: From Reactive Management to Anticipatory Care

Type 2 diabetes mellitus is a highly prevalent, heterogeneous, and progressive chronic disease. In a large proportion of patients, management is based for many years on lifestyle intervention and non-insulin glucose-lowering therapies. This long pre-insulin phase represents a crucial clinical window, in which timely recognition of metabolic deterioration, therapeutic inertia, treatment response, and individual risk trajectories may substantially influence long-term outcomes. However, routine care is still frequently based on intermittent assessments, delayed treatment adaptation, and limited integration of clinical, biochemical, behavioral, and digital data. Artificial intelligence may offer a clinically relevant opportunity to move from reactive management to anticipatory care in non-insulin-treated type 2 diabetes. Rather than replacing clinical judgment or automating treatment decisions, artificial intelligence can support clinicians by identifying hidden patterns, predicting metabolic worsening, stratifying risk, improving the interpretation of glucose data, and personalizing follow-up intensity and therapeutic timing. In this setting, its most meaningful role may be to reduce the silent interval between early deterioration and clinical action. This narrative review discusses the rationale, current applications, near-future scenarios, and implementation barriers of artificial intelligence in non-insulin-treated type 2 diabetes. Particular attention is given to advanced interpretation of glycemic data, clinical decision support, prediction of treatment failure, remote monitoring, and the potential integration of multidimensional data into more precise and timely care pathways. The review also emphasizes the need for explainable, clinically validated, equitable, and ethically governed artificial intelligence tools that can be realistically embedded into everyday diabetology practice.